6,924 reports of this reaction
12.1% of all CINACALCET HYDROCHLORIDE reports
#2 most reported adverse reaction
HOSPITALISATION is the #2 most commonly reported adverse reaction for CINACALCET HYDROCHLORIDE, manufactured by Amgen Inc. There are 6,924 FDA adverse event reports linking CINACALCET HYDROCHLORIDE to HOSPITALISATION. This represents approximately 12.1% of all 57,261 adverse event reports for this drug.
Patients taking CINACALCET HYDROCHLORIDE who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a frequently reported adverse event for CINACALCET HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to hospitalisation, the following adverse reactions have been reported for CINACALCET HYDROCHLORIDE:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 6,924 FDA reports for CINACALCET HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 12.1% of all adverse event reports for CINACALCET HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience hospitalisation while taking CINACALCET HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.